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Abstract
Isolated liver cells (primarily isolated hepatocytes) have found important applications in
science and medicine over the past 40 years in a wide range of areas, including physiological
studies, investigations on liver metabolism, organ preservation and drug de-toxification,
experimental and clinical transplantation. An integral component of many of these works is
the need to store the isolated cells, either for short or long-term periods. This review covers
the biopreservation of liver cells, with a focus on the history of liver cell biopreservation, the
application of hypothermia for short-term storage, standard cryopreservation methods for
isolated hepatocytes, the biopreservation of other types of liver cells, and recent developments
such as vitrification of hepatocytes. By understanding the basis for the different approaches, it
will be possible to select the best options for liver cell biopreservation in different
applications, and identify ways to improve preservation protocols for the future.
Keywords: Isolated hepatocytes; isolated liver cells; biopreservation; hypothermic storage;
cryopreservation; vitrification; sub-zero non-freezing storage; drying.
INTRODUCTION
It is more than 40 years since the definitive studies of Berry & Friend [6] and Seglen
[109] demonstrated that is was possible to isolate individual functioning hepatocytes from
intact rodent livers by enzymatic digestion. This was a major step forward in facilitating
research on biochemical and molecular aspects of liver function and pathology. It became
possible to disaggregate a complex organ, such as the liver into cellular components, whilst
keeping the functionality of its cells. An idea of the structural complexity of the liver is
appreciated in Figure 1. It became possible to isolate not only the hepatocytes (as the major
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fraction of metabolically-active cells) but also other cell types such as sinusoidal endothelial
cells or Kupffer cells; however these are beyond the scope of this review.
The isolation technique has been subjected to various refinements to become a robust and
easily-reproducible method between laboratories. Hepatocytes have been isolated from a
growing number of species including several mammalian species in addition to rodents (such
as dog [69], cat [111], rabbit [24], pig [11], goat [129], sheep [89], and also man [20, 88], and
the technique has been applied in other phyla including fish [103], amphibians [10],
archosaurs [45], and birds [43]. The uses of isolated hepatocytes have expanded over that time
as greater understanding of their potential benefit has been accrued, and now include
widespread use in metabolic studies, drug discovery, and experimental and clinical cell
transplantation [122].
Mature hepatocytes are terminally-differentiated epithelial cells which in normal
physiology possess a wide range of important functions, such as metabolic conversion and
detoxification of xenobiotics, control of intermediary metabolism, interconversion of sugars,
lipids and amino acids, and synthesis of proteins. Whilst mammalian hepatocytes can be
successfully sustained in tissue culture for a few days, they do not undergo replication to any
significant degree, even when stimulated with potent growth factors. The high level of interest
in using cells and the fact that liver tissues can yield high numbers of cells from one isolation
(e.g. for human livers, >2x106 cells per g liver weight [125] have led to an associated need to
preserve the isolated cells to maximise the benefit from isolation, bank large cell numbers for
transplantation or provide good inter-batch comparisons for xenobiotic assays. Over the same
time period, there has been an increasing interest in studying other liver-derived cells, such as
hepatoblastoma cells and liver progenitor cells, often as a way to derive continuously-
replicating cells which possess some of the functional characteristics of mature hepatocytes,
and which also require biopreservation for similar reasons.
Biopreservation methods have been almost exclusively based on applications of low
temperatures, either hypothermic storage in the range of 2-4oC, or cryopreservation to deep
subzero temperatures. In some cases, for specific purposes the hepatocytes require
Figure 1. Liver cell organization. Dual blood supply of the liver merges upon entry into
the liver lobule at the portal field. The four major cell types that are found in the liver are
hepatocytes, stellate cells, sinusoidal endothelial cells and Kupffer cells.
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preservation in different formats such as encapsulated in spheroids of different biocompatible
media, or in monolayers overlain with biopolymers.
This review will provide an overview of 1. The historical background of liver cell
preservation in the early years up to 1990; 2. Current concepts: hypothermic preservation
methods appropriate for a few days; 3. Current concepts :Cryopreservation methods based on
slow cooling regimes; 4. Biopreservation at cryogenic temperatures in altered formats such as
cell encapsulation; 5. Biopreservation of liver-derived cell lines and hepatic progenitor cells;
6. Alternative approaches to hepatocyte preservation, including vitrification, subzero non-
freezing storage or dry state preservation.
1. THE EARLY HISTORY OF LIVER CELL BIOPRESERVATION – PERIOD
UP TO 1990
Early work into cryopreservation of isolated hepatocytes was reported by Le Cam and
colleagues in the mid-1970’s [59] using rat hepatocytes as the most easily available source.
The chosen cryoprotectant (CPA) was dimethyl sulfoxide (Me2SO) at concentrations up to 1.5
M, and exposure was carried out at 4oC, indicating that even in the first experiments, issues
with CPA toxicity were recognised. A range of cooling rates was investigated between -
2°C/min and -100°C/min down to below -100°C as target temperature, before transfer to
liquid nitrogen (LiqN2). Thawing was done rapidly in a water bath at 37°C. The best
recoveries were found when cooling rates were in the range of -2°C to -7°C/min, with
viability by trypan blue (TB) staining at around 80%. Nevertheless, more complex metabolic
mechanisms, assessed by gluconeogenesis, were compromised at around 50%.
The value of using a sugar (in this case, glucose) as an osmotic buffer during a slow
cooling protocol for rat hepatocytes was shown by Fuller et al [37] when using Me2SO as the
preferred CPA. In experimental transplant studies from Kusano et al, [57] rat hepatocytes
recovered after slow cooling / rapid warming using Me2SO were shown to survive
morphologically when grafted into the splenic pulp of recipients as isografts (a location for
heterotopic hepatocyte transplantation which was originally reported by a number of groups at
the time [93] and which remains a mainstay of the procedure until today).
Investigations into other CPA for rat hepatocytes confirmed that Me2SO was superior to
glycerol or methanol using slow cooling / rapid warming, and again the range between
-1°C/min and -10°C/min was optimal as assessed by TB staining and urea synthesis.
However, and once again, more complex metabolism (in this case, protein synthesis)
remained low after recovery. One notable finding was that exposure to Me2SO did not itself
impact protein synthesis, as long as a sugar (in this case, glucose) was used as an osmotic
buffer in the CPA dilution step [37].
Further studies were undertaken where rat hepatocytes during slow cooling with Me2SO
were rewarmed at various intermediate temperatures down to -60°C, the end target
temperature, and even though high yields could be recovered by TB staining, ultrastructural
analyses immediately on thawing showed many changes compared to the starting cell
population [35]. These ranged from mild swelling of mitochondria and cytoplasmic
vacuolation to condensation of organelles into the cell interior and blebbing of the plasma
membranes.
Use of high cooling rates (approximately -300°C/min) resulted in high frequencies of
severe abnormalities with extensive disruption of organelles and cytoplasm, possibly
suggesting intracellular ice formation. Bilirubin conjugation could be measured in rat
hepatocytes recovered after slow cooling, but was not detectable in these rapidly-cooled cells.
In other work, microsomal drug detoxification was partially conserved in rodent hepatocytes
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after slow cooling / rapid warming [92] and again, Me2SO proved to be a better CPA than
glycerol.
During this time, interest in transplanting cryopreserved hepatocytes for liver support, at
least in experimental models, continued to grow, and infusions of cryopreserved rat
hepatocytes were made to support essential detoxification processes in models of acute liver
failure (produced either by surgical intervention or chemical poisoning). In a rodent model,
cryopreserved hepatocyte isografts or xenografts (cryopreserved pig hepatocytes) infused into
the peritoneal cavity both showed evidence of life-sustaining support [71]; however, the exact
functional status of the cryopreseved cells at the point of infusion was unknown, and viable
cells could not be detected in the peritoneum. Nevertheless, using intrasplenic transplantation
in rodents, several groups were able to show long-term survival of at least a population of
cells from cryopreserved hepatocytes [36, 68]. Rat hepatocytes cryopreserved using slow
cooling and Me2SO as CPA could be identified in the spleen at 6 weeks after grafting, and
post-thaw recoveries could be evaluated by significant uptake of the radio-labelled scanning
agent HIDA. Similar results were reported using slow cooling/ Me2SO as CPA by another
group [32].
Alongside the studies on rodent hepatocytes, gradual refinement of the cell isolation
methods permitted good recoveries of functional cells from livers of larger animal species and
human livers. Cryopreservation was equally important for the work, which in this era was
focused mainly on hepatocytes as models in drug metabolism and toxicology. The standard
accepted protocol continued to be slow cooling with Me2SO and rapid warming, which
provided human hepatocytes post-thaw with good recovery of ultrastructural morphology [87]
and drug metabolising activities [64]. However, in most cases and for different drug
metabolising pathways, the cryopreserved hepatocytes showed reduced functions when
compared with freshly-isolated cells. Intracellular ice formation or exposure to hyperosmotic
solutions remain the main issues of cryopreservation process, and their effects on cell quality
and cell death induction must be clarified.
Throughout the same time span, some investigators performed studies on hepatocytes
preserved by hypothermic storage, both for practical short-term preservation to meet
laboratory demands, and as a tool to investigate the compositions of novel hypothermic
preservation solutions for whole organ storage for transplantation. The advantages of using
isolated liver cells, obtained in large numbers from one liver perfusion, include the ability to
test several variables within one experiment, and to have an easily manipulable test system
where drugs or additives can be directly delivered to the cells in known doses.
Isolated rodent hepatocytes were used by Umeshita and colleagues to investigate the role
of calcium in the preservation solution for hypothermic storage (2°C) between 12-72h [128],
and Kravchenko studied morphological characteristics [52]. Fox et al [31] in Belzer’s
laboratory studied the importance of pH control when storing hepatocytes in either organ
preservation solution (UW solution) or tissue culture medium over the same time period.
Belzer’s group went on to further investigate the role of colloids such as polyethylene glycol
[76] and amino acids in the supporting medium [74] during hypothermic storage. It was
generally agreed from these early reports that cold preservation injury increased beyond 24h
storage, and was significant by 72h.
2. CURRENT LIVER CELL BIOPRESERVATION - HYPOTHERMIC
STORAGE
Considering the relative sensitivity of hepatocytes to cryogenic preservation (see Section
3), hypothermic storage of hepatocytes in suspension is still a method of choice in many
practical situations due to simplicity and ability to study basic principles of cellular
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metabolism under cold hypoxia. Isolated liver cells also became an essential part of the field
of cryobiology that outlined competent methods for cell preservation and clinical application
for treating various forms of liver failure [34, 44] over the past three decades. Nevertheless,
hypothermic preservation imposes a considerable impact on isolated liver cells. It is further
compounded by the fact that hypoxia in the sample may develop when the hypothermic cell
suspensions are kept in tubes or vials without further oxygenation – hepatocytes, being large
cells, will readily sediment by gravity into densely-packed agglomerates -. The major
challenges are characterized by multiple biochemical and ultrastructural changes (see figure
2) which can be summarized as follows:
 Perturbation of ion balances caused by hypothermia, notably mono- and
divalent cations (Na+, K+, Ca2+) and anions (Cl-).
 Osmotic swelling.
 Shift in extracellular and intracellular pH.
 Oxidative stress.
Figure 2. Hypoxia-reoxygenation phenomena in hepatocytes. Hypoxia, leading to fall in ATP
and increase in H+, affects membrane transporters and internal ion balances. Along with
enzymes activation, cell and mitochondrial membrane injury occurs, leading to apoptosis and
other molecular degradation. On re-oxygenation, injured mitochondria and ongoing enzymatic
processes increase oxidative stress, and amplify the injuries via additional inflammatory
processes.
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a) Perturbation of ion balances.
Inhibition of the Na+/K+ ATPase causes cell edema, rapid depletion in ATP reserves, and
a corresponding increase in ADP levels, and this depletion of ATP leads to the degradation of
adenosine causing accumulation of hypoxanthine and xanthine oxidase. Cell membrane
depolarisation also occurs very early in the cascade leading to a breakdown of ion
homeostasis, and interplay of other intracellular and membrane - associated events that
eventually culminate in cell death by either apoptosis or necrosis [41].
i) Perturbation of monovalent cations
Change in barrier function of liver cell membranes to monovalent cations and anions (K
+, Na+, Cl-, H+) is well-recognized, leading to conditions of hepatocyte cellular water
accumulation [15, 42]. Direct evidence showed that cooling of hepatocytes caused a K+ loss
and was accompanied by the intracellular diffusion of sodium and chlorine with associated
volume increase [7].
ii) Calcium perturbation caused by hypothermia
Calcium plays a crucial role in biological systems. It is a universal cellular regulator of
cell-to-cell interactions and mechanisms implemented to change cellular metabolism
according to environmental conditions such as hypothermia. Loss in barrier function of cell
membranes, particularly for bivalent cations, ensures a more severe injury of membranes and
has a significant impact on hepatocyte function [29, 42, 128]. Cooling and changes in cell
volume are drastic factors that mobilize calcium from intracellular depots [97]. Even short
cold exposure of hepatocytes (20 min) in UW solution may cause a significant loss of
intracellular Ca2+. The main intracellular Ca2+ depots are endoplasmic reticulum and
mitochondria which appear to be susceptible to hypothermia and promote rapid Ca2+ release
[48]. Concomitant pretreatment with calcium blockers in the relevant intracellular
compartments may stimulate ATP regeneration and improve hepatocyte cellular hypothermic
preservation [28].
The optimal concentration of calcium in cellular environment may be a crucial factor for
cell viability. Umeshita et al [128] suggested that optimal Ca2+ concentrations of the
preservation solutions were within narrow range 0.3-0.5 mM. Addition of combinations of
electrolytes of Ca2+/ Mg2+ to the L-15 preservation medium suppressed hepatocyte swelling,
increased endogenous respiration and improved viability during 48-hours cold preservation
[74]. The possible protective mechanism of calcium may be attributed to cytoskeleton
stabilization, followed by inhibition of bleb formation on plasma membranes and a decrease
in LDH release [48]. The problem of Ca2+ concentration in the storage medium is often
discussed in relation to UW solution. Lactobionic acid, which is a component of the solution,
and similar to phosphate, can chelate calcium ions [46] hence substantially influence the
divalent cation distribution between the hypothermic preservation solution and cytoplasm.
b) Counteracting osmotic swelling.
Swelling was one of the earliest changes registered in cold-preserved hepatocytes [7, 42,
76]. Many papers have recognized a link between alterations in ion balances, progressive
edema and the loss of cellular viability [34, 75, 128, 130].
A major advancement in cold preservation has been made by including cell-impermeant
osmotically active molecules to prevent the cold-induced swelling. Low-molecular weight
substances such as glucose and galactose have shown little effect against edema. However,
mannitol, lactobionate and sucrose, substantially improved hepatocyte integrity and can be
considered to be the most popular choices as additives in hypothermic preservation.
Polymeric substances with osmotic and oncotic properties such as polyethylene glycols
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(PEGs) of different molecular mass (from 8 to 35 kDa) were shown to prevent effectively
liver cell swelling, reduce LDH release and increase viability [73]. Similar substitution of
PEG by dextran (5%) or saccharides (100 mM) neither prevented cell swelling nor protected
the cells from death [76]. Based on personal experiences we noticed that, due to some sort of
artifact, isolated cells in presence of PEG become refractive to trypan blue. For unexplained
reasons, the viability assessed by trypan blue exclusion after cold storage, appears to be
generally above 95% when trypan blue is assessed in media which contain residual PEG,
irrespective of the treatment or real quality of cells. This is probably due to a synergistic effect
between the interactions of the hepatocyte plasma membrane, the PEG, the low temperatures,
and the trypan blue, reducing dye influx into injured cells during the analysis.
c) Significance of pH buffers during hepatocyte cold storage.
Maintenance of cell volume is closely related to cytosolic pH values via ion transport
systems and exchangers such as Na+/ H+, Cl-/ HCO3- and the Na+/HCO3- symport which
influences intracellular pH [83, 91]. In combination with low temperature, pH deviations may
destabilize lysosomes and promote release of dehydrogenases in the mitochondrial matrix,
with associated initiation of apoptosis [113]; and the situation becomes even more complex
after rewarming. A return to normothermia disturbs regulatory mechanisms by attenuating
Na+/H+ exchange and increasing Na+/HCO3- cotransport, whereas Cl-/HCO3- exchange is not
affected [91].
At onset of cold hypoxia the expected pH shift to low values as H+ accumulate, is
compensated to some degree by buffering capacity of the cytosol [26]. According to the
‘alpha-stat’ theory, regulation of cellular pH in poikilothermic or homoeothermic animals is
dependent on the temperature-dependent ionization of the α-imidazole group of histidine of
cytoplasmic proteins [102], which results in a natural and opposing apparent alkaline shift in
pH [25]. Histidine and carnosine were found to effectively prevent acidosis due to penetration
and distribution in liver tissues [19, 114]. Citrate as a buffer was shown to penetrate and even
modulate substrate turnover during cold storage, enhancing late hepatic synthesis of succinate,
with possible metabolic benefits [66, 115].
The significance of pH stabilization and prevention of acidosis by a strong buffer system
is an often-debated topic. It is well-defined that intracellular acidification can mediate the
protective effects of hypothermic preservation on metabolism by one or more intracellular
stress-activated enzymes such as phospholipase A. Cyclosporine A administration, which
amongst other actions, blocks cytochrome с release from mitochondria (but not the rise of
intracellular pH), significantly improved hepatocyte viability after reperfusion, suggesting the
pivotal role of mitochondria in this process [101].
d) The role of antioxidant defense during cold storage.
Despite the fact that the end product of the electron transport through the mitochondrial
respiratory chain is water, which is formed by the 4-electron reduction of molecular oxygen
by cytochrome oxidase, part of the oxygen reduction machinery may be involved in one-
electron reduction reactions, forming free radicals and oxidants such as superoxide anion O2-,
hydrogen peroxide (H2O2) and most reactive hydroxyl radical •OH [113]. In vivo only a small
portion of oxygen (approximately 5%) processed via mitochondrial respiration, is spent on the
formation of O2- [113], but hypothermia and hypoxia lead to a significant increase of
superoxide anion formation. Together with available data on significant production of
reactive oxygen species (ROS) by mitochondria and their role in oxidative damage, Ohkohchi
et al, demonstrated that the concentration of O2- in intact mitochondria is 2-3 thousand times
lower than in sub mitochondrial particles. Therefore, only minor amounts of O2- “escape”
from the mitochondria, which is potentially damaging to their own stability [96], and
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providing antioxidants to the preserving solutions during hypothermic storage of liver cells is
one feasible way to increase the overall antioxidant defense.
The relative high resistance of hepatocytes to oxidative stress, compared with endothelial
cells, may be attributed to a high antioxidant capacity of hepatocyte cytoplasm. For instance,
the concentration of reduced glutathione (GSH) in the intercellular space is around 10 µM,
whereas its cytoplasmic concentration is more than 1000 times higher [58]. Although high
levels of GSH can be present in native cells, hypothermia causes rapid depletion of the
tripeptide [131]. It has been found that GSH content in whole liver after 5-6h cold storage
dropped by 51%, and then by another 23% after subsequent reperfusion [134]. It is assumed
that during hypothermia, hepatocyte plasma membranes become permeable to GSH [105].
Administration of exogenous GSH or methionine and their combination substantially slowed
the GSH loss and protected viability during rewarming of cold-preserved hepatocytes [72].
The effectiveness of other antioxidants, such as those of plant origin, has been demonstrated
in randomized studies. Silibinin from Silybum marianum added to preservation solution was
beneficial for ATP content, reduction of lipid peroxidation, mitochondrial function and
hepatocyte survival after storage at 4 degrees C. [54]. A water-soluble analogue of α-
tocopherol provided antioxidant action during prolonged hepatocyte cold preservation up to
72 hours. This was accompanied by membrane stabilization thorough cytoskeleton proteins
[48].
Many studies during the past decade have suggested a leading role for xanthine oxidase
(XO), a powerful source of H2O2 and O2 in hypothermic injury. XO inhibitors, such as
allopurinol, demonstrated good scavenging ability during reperfusion of whole liver after
hypothermic storage [47, 91]. It is important to note that inhibitors of XO, including
allopurinol, are not totally effective, so the enzyme may still accomplish the electron transfer
to oxygen thus generating superoxide [83]. Other XO inhibitors such as 4-Amino-6-
hydroxypyrazolo pyrimidine (AHPP) lack such a propensity for radical leakage however, they
may be associated with other toxicities which have prohibited wider clinical application.
Although it is uncertain whether this finding is important for hypothermic storage of liver
cells, it is important to realise that pharmacological properties of any drug may be different
depending on temperature, different species or type of preservation solution. Development in
the future of XO inhibitors which do not have a pro-oxidant action, similar to allopurinol,
with associated minor side effects, would be an advantage.
3. CURRENT LIVER CELL BIOPRESERVATION: CRYOPRESERVATION OF
CELL SUSPENSIONS
It has become a very essential problem to develop relatively simple and reliable methods
for cryopreservation of isolated liver cells for long-term cryo-banking across a range of the
applications discussed above. Despite the large number of papers devoted to this subject, the
task of maintaining high levels of metabolic status in cryopreserved hepatocytes is still largely
unresolved.
It must be remembered that isolated primary hepatocytes seem to be very sensitive to a
number of factors associated with preservation, which include the important variables of the
sources of the cells, and the methods used for their isolation. The initial state of the isolated
hepatocytes may play a significant role in their responses to cryopreservation procedures. The
donor species and size of the liver segment used for cell isolation, the original technique of
liver procurement and its state (normal or pathological physiology, fat content, etc.) as well as
duration of warm and cold ischemia; all have influences on the yields and viabilities of the
isolated cells, most commonly produced by the enzymatic digestion method. However, for
hepatocyte isolation, it should be pointed out that there are two approaches for liver
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disaggregation. The most common approach includes two-step collagenase perfusion protocol
[109], which disintegrates the extracellular collagen matrix. The final suspension of
hepatocytes is obtained after mechanical dissociation, filtration and low speed centrifugation.
Another different approach for hepatic cell isolation [53] allows an easy release of
hepatocytes from small animal livers by a combination of liver perfusion at 37°C with
calcium chelator, EDTA, followed by soft tissue disaggregation. The conditions during
isolation must be carefully controlled; otherwise, problems of latent injury may arise in cells
with damaged or altered cell membranes [121] which may impact in a negative way on
subsequent cryopreservation.
For cryopreservation, the various important variables can be divided into four main
categories: a. cryopreservation base medium; b. CPA type and conditions of addition and
removal; and c. Cooling and warming profiles.
a) Cryopreservation base media
Commonly, the base of cryoprotective medium composes isotonic salt solution in
extracellular concentration. Correspondingly, culture media such as RPMI-1640, Dulbecco’s
modified Eagle’s medium (DMEM), etc. are widely used as base solutions for
cryoprotectants.
Later, solutions of “intracellular type” initially developed for hypothermic storage of
organs for transplantation, were applied for hepatocyte cryopreservation. The “gold standard”
of these solutions is University of Wisconsin (UW) solution, which contains the impermeable
anion lactobionate (100 mM) and the impermeable saccharide raffinose (30 mM) [56].
Comparison of UW solution with three other solutions (DMEM, Cell Banker 1 and Cell
Banker 2) for cryopreservation of hepatocytes with 12% Me2SO and 10% fetal bovine serum
demonstrated beneficial effect of UW solution on viability, enzyme release and plating
efficiency of rat hepatocytes [5].
Application of UW solution is limited by rather high cost; therefore other solutions of
intracellular-type were tested for hepatocyte cryopreservation. Sucrose-based solution allowed
high post-thawing levels of rat hepatocyte viability, energetic parameters, cationic
homeostasis [98] and O-demethylation of p-nitroanisole (CYT P450 activity) [81].
A recently developed dextran-based intracellular-type freezing solution, HypoThermosol
(HTS), showed benefits when compared to DMEM in viability rate, albumin secretion, urea
synthesis, deethylation of ethoxyresoruﬁn (CYT P450 activity), and responsiveness to 
stimulation with interleukin-6 after rat hepatocyte cryopreservation with 10% Me2SO [118].
However, data comparing UW to other intracellular-type solutions are unavailable in the
literature.
b) CPA type and conditions of addition
Since hepatocytes are very cryolabile cells and their freeze-thawing without CPA results
in the death of all cells in suspension a penetrative CPA such as Me2SO, glycerol,
propanediol, etc. is required. In most studies, Me2SO demonstrated better recovery than
propyleneglycol [100], propanediol and glycerol [14, 37]. In the study performed by Mazur et
al, viability rate and detoxification activity of hepatocytes after cryopreservation with 1.4 M
Me2SO, glycerol, dimethylacetamide (DMAC) and 1,2-propanediol were compared [81].
Me2SO and glycerol had higher cryoprotective effects than DMAC and 1,2-propanediol. Use
of Me2SO and glycerol showed similar high ability to preserve biotransformation of p-
nitroanisole in isolated hepatocytes after cryopreservation.
The optimal concentration of Me2SO in the cryopreservation medium comprises 1.25-2.5
M [14, 100], though usually its final concentration is 1.4 M, because higher concentrations are
toxic.
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Non-penetrative CPAs singly added to cryopreservation medium seem to not show a
protective effect. However, their presence along with Me2SO can increase cell survival and/or
reduce the concentration of penetrating cryoprotectant. Thus, in a cryoprotective medium with
Me2SO, the addition of di-, tri-, and tetra-saccharides enhanced: viability, attachment to
plastic and metabolic activity of rat and human hepatocytes in culture [85]. Among
saccharides the most promising seems to be natural disaccharide trehalose, which
demonstrated positive effects on the quality of not only several cell types, such as sperm
[132], human oocytes [29], and erythrocytes [65], but also engineered tissue substitutes [13].
Supplementation of standard cryopreservation medium containing 10% Me2SO with trehalose
significantly improved post-thaw primary human hepatocyte viability, enzyme leakage,
albumin and urea formation, cytochrome P 450 (CYP)-dependent xenobiotic metabolism, and
plating efficiency. The useful property of trehalose to prevent cell death in cryopreservation
probably is due to its ability to stabilize phospholipids and proteins during dehydration [27].
The inclusion of trehalose and related sugars (glucose, maltotriose) in the cryopreservation
fluid in addition to dimethyl sulfoxide (10%), first tested with primary rat hepatocytes cooled
in a controlled rate freezer, showed, after thawing, significantly higher viability based on TB
of cells frozen in oligosaccharide-supplemented medium than for those cryopreserved without
oligosaccharides [85].
The efficiency of supplementing the CPA base medium with high molecular weight
polymers such as polyethylene glycols (PEG), to allow a reduction of Me2SO concentration
has not been demonstrated in hepatocytes although it has been successful with other cells
[63]. This may be due to the presence, in the CPA medium, of other polymers such as
albumin, serum or other impermeable molecules.
c) Cryopreservation/thawing protocols.
Crucial to the outcome of cryopreservation are the cooling and warming rates. Slow
freezing protocols that allow avoidance of intracellular ice formation are most common for
adult hepatocyte cryopreservation. For the same purpose, at the stage of re-warming most
researchers use rapid thawing at 37-40°C.
Seckiguchi et al [107] have shown that during the freezing of isolated hepatocytes down
to -196°C at a rate of 1°C/min with 1.5 M Me2SO and rapid thawing, the viability of cells
after a month of storage in liquid nitrogen was 60% of the control value. Similar results were
obtained in another study using slow freezing and rapid thawing of suspensions in the
presence of 1.5 M Me2SO [100]. Very similar viability (50-65%) was obtained [23] after
cryopreservation of human hepatocytes in medium containing 10% Me2SO and 20% fetal calf
serum using a programmed freezing rate of -1.9°C/min from 4 to -30°C and then -30°C / min
from -30°C to -150°C.
Various metabolic processes of liver parenchymal cells have varying degree of
cryosensitivity. Slow freezing of isolated liver cells (2°C/min) described in [94] yielded a
high percentage of surviving cells frozen to -196°C; however, on closer inspection, the same
freezing protocol applied to -30°C resulted in a number of cells with multiple morphological
defects [35]. The rate of urea synthesis was depressed by 50% of freshly isolated cells.
Freezing at a rate of 50°C/min causes significant reduction of viability of the suspension.
Consequently, slow freezing rates are considered more appropriate for hepatocyte
preservation.
The problem with slow cooling rates is the extension of time that cells spend at relatively
high subzero temperatures in the residual liquid fraction prior to achieving the ‘quasi-
vitreous’ state at ultra-low temperatures. During this time cells are exposed to high salt
concentrations, and toxic CPAs. Besides, slow cooling allows sedimentation of cells on the
bottom of the vials, where cell density become higher than the optimal, resulting in additional
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cell damage. According to metabolic parameters like cytochrome CYP3A4 activity, lactate
dehydrogenase release and bilirubin conjugation measured after rewarming, cell
concentrations from 106 to 107 cells/ml proved to be optimal [125]. However, De Loecker et
al [17, 18] suggested that even lesser cell density of hepatocytes may increase hepatocyte
viability after thawing. These results indicate that unless a high cell density of cells are
specifically needed; samples with a low cell count (less than 107 cells/mL) are preferable.
Several methods are available for preventing sedimentation of cells: mixing samples at
the initial stage of cooling [14], seeding [33] and using a rapid two-step cooling protocol.
The importance of ice seeding has been shown in study [100]. Isolated hepatocytes were
equilibrated for 5 min with 0.5 M Me2SO at room temperature, placed in a bath at 1-2°C
below the ice nucleation temperature and induced ice seeding. Samples were cooled at various
rates down to -60 ° C and then transferred to liquid nitrogen. The most effective were the
cooling rates in the range from 0.5°C/min to 10°C/min. The synthesis of urea after rewarming
was maintained at 50% and protein synthesis rate was only 25% of the freshly isolated cells.
A rapid two-step cooling protocol first developed for fibroblasts [30] was adapted for rat
hepatocyte cryopreservation with 10% Me2SO [81, 98]. For successful application of the
protocol it was important to discover a safe temperature range which, on one hand, permitted
rapid and complete crystallization of extracellular medium but, on the other hand, prevented
supercooling of liquid, which promotes formation of intracellular ice crystals, lethal for cells.
The best temperature range was found to be between -20°C and -25°C. This protocol has been
shown to significantly maintain viability, gluconeogenesis, mitochondrial and ion-
transporting functions and (CYP)-dependent xenobiotic biotransformation in a wide range
(5×106 - 5×107 cells per ml) of hepatocyte densities.
4. CURRENT LIVER CELL BIOPRESERVATION: CRYOPRESERVATION IN
ALTERED FORMATS - ENCAPSULATED OR SANDWICH
CONFIGURATIONS.
One important consideration in translational studies using isolated hepatocytes for drug or
metabolic investigations depends upon the nature of the in vitro culture systems which are
applied; it has been known for some time that expression of normal liver phenotype may be
best supported if the hepatocytes are provided with matrices which can maximise cell-cell
contact in either 3-dimensional configurations or sandwich culture [90]. These ideas have
been translated through to cryopreservation protocols, which then often require the low
temperature preservation steps to be undertaken in receptacles such as multi-well tissue
culture plates.
Sandwich culture where liver cells can be cultured between two layers of matrix such as
collagen was developed more than 20 years ago, and early attempts to cryopreserve
hepatocytes in this format produced low survivals [8]. One of the earliest successful reports of
this approach was made by Koebe and colleagues [50] cryopreserving rat hepatocytes which
had previously been delivered into a sandwich culture between two layers of collagen. The
chosen CPA was 15% Me2SO, and the tissue culture flasks were cooled at a slow rate to
-70°C, with subsequent storage at -100°C. Rewarming was rapid, and some recovery of
albumin secretion was noted, although lower than for control cells. The study was extended
by Borel-Rinkes et al [9], who used a similar culture configuration and cooling rates of
-5°C/min and an end temperature of -80°C, when 70% of pre-cryopreservation levels of
albumin secretion could be obtained. Koebe went on to develop a specifically-designed
cooling chamber where porcine hepatocytes in sandwich culture could be cryopreserved in
tissue culture flasks [49]. Incubation with CPA (10% Me2SO) was performed for 15 min at
37°C, before cooling at either -1°C or -10°C/min to -80°C as an end temperature; the flasks
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were held in storage for either 3 or 30 days, before rapid rewarming and CPA dilution in
stepwise manner at 4°C. Both albumin secretion and drug metabolism were measured, and it
was shown that slow cooling (-1°C/min) was superior to faster (-10°C/min) rates, whilst the
position of the flasks within the cooling chamber was important (attributed to different
impacts of the cold nitrogen vapor pumped into the chamber). With the optimal
cryopreservation protocol, storage for up to 30 days did not affect outcomes. The same group
[51] went on to refine the technology for the cooling chamber, and reported 75% recovery of
functions in porcine hepatocytes stored for 14 days at -80 °C.
Cryopreservation in the sandwich configuration has recently been applied to porcine
hepatocytes in a flat membrane bioreactor configuration which might be suitable for a liver
support device [39]. Slow cooling (-1 °C/min) with 10% Me2SO was again selected with an
end temperature of -80°C. Storage for a maximum of 14 days was carried out, with rapid
rewarming and step-wise CPA dilution. Albumin secretion, urea synthesis and ethoxy-
coumarin activities were recovered to about 60% of non-frozen controls by days 11 or 14 of
storage.
More recently it was shown that, whilst monolayer (single layer gel) cultures of
hepatocytes could be cryopreserved under similar conditions, in this format, the cells lost up
to 50% of reduced glutathione content when recovered after 24h from -80°C [120]. Inclusion
of antioxidants during cryopreservation reversed this trend, but not completely.
Cryopreservation of rat hepatocyte monolayers was also reported for cells cultured on
collagen vitrigel membranes, produced by dehydrating collagen gels to a glassy state on a
supporting matrix [84]. Slow cooling at -1°C/min after exposure to 10% Me2SO was followed
by storage in liquid N2 and rapid rewarming. Much higher recoveries of attached viable cells
were reported for vitrigel compared to cryopreservation of monolayers on normal plastic
culture plates, and on vitrigel, the liver cells maintained typical polygonal morphology.
Another approach to cryopreservation of liver cells in 3-D configuration has been to
either attach the hepatocytes onto microcarrier beads, or encapsulate the cells in alginate
microspheres, relying on the adherence of functional cells, or the ability to mix cells and
alginate before expulsion as droplets into a polymerizing buffer. Early studies focused on
cryopreservation of adult hepatocytes attached to alginate-poly-L-Lysine-collagen
microcarriers for liver cell transplant studies [21], with evidence of metabolic activity of the
cryopreserved transplants by correction of hyper-bilirubinemia. Mahler and colleagues [70]
encapsulated rat hepatocytes in 2% alginate micro-beads. Cryopreservation was carried out by
a 2-step cooling method (with holds at -20°C and -80°C before transfer to liquid nitrogen),
Me2SO at 16% and rapid warming. Results showed that viable cell recoveries were about 85%
of fresh cell numbers, whilst ethoxy resorufin de-ethylase and glutathione transferase
activities were well preserved. Stimulation of post-thaw apoptosis was greatly reduced by
alginate encapsulation compared with that seen in hepatocytes cryopreserved in free cell
suspension. Aoki et al [4] reported alginate encapsulation of rat or human hepatocytes, in
1.5% alginate, and finally coated with poly-L-Lysine. Cryopreservation was carried out using
10% Me2SO in 1.8 ml cryovials, rapid immersion in liquid nitrogen, and rapid rewarming.
Morphology of the encapsulated hepatocytes was well maintained, urea synthesis was about
90% of control values after cryopreservation, and expression of CYP 450 enzymes at a
transcriptional level was demonstrated for the microspheres cultured for up to 7 days after
thawing. When the thawed encapsulated cells were used in a hepatocyte transplant model,
function could be demonstrated throughout 1 week of studies. The same group [126] went on
to show that uptakes of drugs such as salicylate, allopurinol and prostaglandin were well
preserved in thawed encapsulated cells, which had been cryopreserved for up to 120 days and
held in liquid nitrogen.
444
Hepatocytes can also be induced to form 3-D aggregates by rotary culture, in the absence
of added matrix. Lee and colleagues [60] produced rat hepatocyte spheroids, and exposed
them to 10% Me2SO as CPA in 4 different base media (UW solution, Williams E medium,
fetal bovine serum or a mixture of all these). A programmed slow cooling profile was applied.
Although data on ultrastructural stability of the thawed aggregates were not reported, UW
solution proved to be the best CPA carrier solution when assessed by the MTT viability assay
and albumin secretion.
In some cases, alginate encapsulation has been performed after cryopreservation as a way
to either stabilize the thawed cells, or provide a matrix for cell transplantation. Son et al [117]
cryopreserved rat hepatocytes in cell suspension using a 2-step cooling regime (-20°C, then -
80°C before transfer to liquid nitrogen), and after rapid rewarming, immobilized the cells in
2% alginate supplemented with collagen and chitosan. The encapsulated thawed cells showed
higher levels of urea synthesis than hepatocytes thawed and cultured directly.
Alginate encapsulation and cryopreservation has also been promoted for liver cell lines
such as HepG2 cells, where large numbers of cells may be needed for bioartifical liver
support. Cryopreservation of alginate-encapsulated liver cell spheroids produced by culturing
HepG2 cells within 1% alginate was carried out using a slow cooling regime (-2°C/min), 10%
Me2SO as CPA, and storage in liquid N2 [77]. Good recoveries of viable cell numbers, protein
secretion and broad spectrum CyP 450 functions were reported. The work demonstrated the
importance of control of ice nucleation (‘seeding’) during the cooling phase which reduced
cryopreservation-induced apoptosis and improved viabilities which were tracked in culture up
to 72h post-thawing. Albumin synthesis was also recovered after cryopreservation of the
alginate-encapsulated liver cell spheroids after cooling using an electrically-powered cryo-
cooling machine based on Stirling motor technologies [78].
5. BIOPRESERVATION OF LIVER CELL LINES AND HEPATIC
PROGENITOR CELLS.
A number of liver cell lines, mainly of hepatoblastoma derivation, are available
(including HepG2, C3A, and HuH-7 lines). As continuously-growing transformed cells, they
present much less of a problem for cryo-banking, and they are routinely cryopreserved in
many laboratories using simple slow cooling methods and Me2SO as CPA. Regulated sources
of HepG2 cells are routinely cryo-banked and supplied by agencies such as European
Collection of Cell Cultures (ECACC), and little specific focus has been paid in recent times
on details of the cryopreservation protocols. Some information does exist where the cell lines
have been used for a specific purpose.
Shoji [110] and colleagues developed a cytotoxicity assay method which included cryo-
banking HepG2 cells attached to collagen substrate in microtiter plates. The CPA was 10%
Me2SO, with slow cooling (about -1°C/min) to an end temperature of -85°C. End storage
temperatures of -4 or -20°C provided functional cells after 2-4 days of storage, but only -85°C
was adequate for long-term (30 day) storage. Zhu [136] and colleagues applied
cryopreservation to HepG2 cells which had been transiently transfected with a specific drug
receptor, as a way to cryo-bank samples and control large volumes of the cell product. The
authors found that the cryopreserved transfected cells functioned as well as fresh transfected
cells, when applying a slow cooling protocol with 10% Me2SO and 20% fetal bovine serum in
the CPA solution, an end temperature of -80°C and rapid warming. Menze and colleagues
[82] investigated a pre-conditioning strategy before cryopreservation of a number of cell lines,
including the liver subclone HepG2/C3A cells, applying slow cooling (-1°C/min) and ice
‘seeding’ at -6°C, and found that the metabolic preconditioning allowed a higher recovery of
C3A cells.
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In experimental models, which induce liver damage and simultaneously block hepatocyte
proliferation, the recruitment of a hepatic progenitor cell population comprised of oval cells is
invariably observed. Hepatic oval cells involved in some forms of liver regeneration express
many markers also found on hematopoietic stem cells (HSCs). There is a substantial body of
evidence to suggest that oval cells are involved in liver regeneration, as they differentiate into
hepatocytes and biliary cells. The supply of human hepatic stem cells (hHpSCs) and other
hepatic progenitors has been constrained by the limited availability of liver tissues from
surgical resections, rejected organs from organ donation programs, and by the need to use
cells immediately.
To facilitate accessibility to these precious tissue resources, recently there has been
published an effective method for serum-free cryopreservation of the cells, allowing them to
be stockpiled and stored for use as an off-the shelf product for experimental or clinical
programs. The method involves use of buffers, some serum-free, designed for
cryopreservation and further supplemented with hyaluronans (HA) that preserve adhesion
mechanisms facilitating post thaw culturing of the cells and preservation of functions [127].
However, the bulk of published data on the role of bone marrow stem cells in liver damage
suggest that they do not play a significant physiological role in replacement of epithelial cells
in any known form of hepatic injury. Fully functional bone marrow-derived hepatocytes
indeed exist, but are extremely rare and are generated by cell fusion, not stem cell
differentiation [22].
There is currently an increasing interest in applications of liver progenitor cells across a
range of scientific areas including both regenerative medicine and biotechnology, which raise
a need for cryo-banking. Historically, fetal liver cells have been seen as important progenitor
cells. The features of fetal tissues compared with adult tissues are a high proportion of stem
cells, as well as a relatively small proportion of completely differentiated cells.
Fetal liver is formed from the derivatives of different germ layers and contain
hematopoietic, hepatic, endothelial and stromal cells of different degrees of maturity [95]. The
proportion of the hepatic cells increases whereas percentage of hematopoietic cells decreases
during prenatal development. The complex cellular hierarchy of fetal liver raises the potential
issue of different responses of its’ constituent cells to the cryopreservation procedure.
Within the cellular hierarchy of fetal liver the largest clinical potential have
hematopoietic stem / progenitor cells, which have high self-renewal capacity and low
immunogenicity [62, 86]. Furthermore, human fetal liver also contains committed
hematopoietic progenitors, mainly erythroid precursors of different maturation stages, which
could be valuable in the treatment of different forms of anemia. Therefore, the majority of
protocols used for the cryopreservation of fetal liver cells is aimed at maintaining the pool of
hematopoietic cells and are based on protocols developed early on for the hematopoietic bone
marrow derived cells.
Usually, human fetal liver hematopoietic cells are cryopreserved by using slow cooling
rates under the protection of 5–10% Me2SO, supplemented with fetal serum [123]. This
protocol allows one to save the majority of hematopoietic progenitor cells. Modification of
the cryoprotective medium by introducing a non-penetrative sugar such as sucrose, enables a
reduction in the concentration of Me2SO, a reduction or replacement of serum and an increase
in the efficiency of cryopreservation [99].
Suggestions for improvement in the protocol by adding membrane stabilizers and
antioxidants have been made in a research study [61] where both the hematopoietic fraction
from fetal liver and cord blood cells (another potential progenitor cell source) were studied.
The authors used end-storage temperatures of -80°C and -196°C, and reported some
differences in efficacy of different additives. However, this cryopreservation protocol was
ineffective to preserve fetal liver stromal cells, which are an important source of multipotent
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mesenchymal stromal cells (MSCs). It has been shown [112], that stromal cells in primary
fetal liver suspension are dramatically sensitive to the cryopreservation procedure, in
particular to supercooling. Only the addition of ice-seeding to the 3-step freezing protocol
allowed it to protect colony-forming activity and the capacity for multilineage differentiation
of MSCs.
Data on the response to the cryopreservation procedure of hepatic cells in fetal liver is
absent from the literature. Their sensitivity can be judged only indirectly. Thus, it was shown
[99] that the cryopreservation of human fetal liver cells using 5% Me2SO resulted in a 15%
decrease in viability of CD34+ cells, as assessed by 7-AAD staining. Very similar reduction in
viability was obtained after cryopreservation under the same conditions of glycophorin A-
positive cells containing as its main population (about 90%) hematopoietic cells in fetal liver
[124]. However, alamar blue reduction rate indicated that the viability of all cells in fetal liver
was decreased 2 fold. Taking into account that the percentage of hepatic cells in human fetal
liver in the 1st gestation trimester of gestation is second only to that of hematopoietic cells and
far higher than for other cell types, we can assume that they, at least, are more sensitive to
cryopreservation procedure than hematopoietic cells. Of course, to answer this question a
special investigation is necessary.
6. ALTERNATIVE APPROACHES TO LIVER CELL BIOPRESERVATION:
VITRIFICATION TO AVOID ICE FORMATION; SUBZERO NON-
FREEZING PRESERVATION; PRESERVATION BY DRYING.
Whilst cryopreservation has been the mainstay of true long-term storage of hepatocytes
over the past decades, some alternative approaches have been researched to improve
outcomes by avoiding the presence of ice altogether. These can be grouped into: a)
vitrification; b) sub-zero non-freezing storage, and c) preservation in the dry state.
a) Vitrification
The process of vitrification involves cooling to deep cryogenic temperatures after
exposing the hepatocytes to high concentrations of CPA (in the region of 40-60% w/v) with
subsequent rapid cooling to avoid ice nucleation. Typically, fast warming rates are also
necessary to avoid ice nucleation during the rewarming phase. So far, few groups have
investigated vitrification for hepatocytes [119]. LL Kuleshova, et al [55] have used
microencapsulated hepatocytes as a model to develop a method of vitreous cryopreservation
for large quantities of cell-containing constructs. This procedure involves the idea that the
scaffold and matrix are expected to support cell colonization, migration, growth and
differentiation, and to guide the development of the required tissue, liver in this case.
Cryopreservation can be achieved by conventional freezing and vitrification (ice-free
cryopreservation). By using sucrose, a sugar that does not penetrate the cells, in combination
with ethylene glycol, they were able to cryopreserve up to 5x106 hepatocytes. The method
included a pre-equilibration procedure in which the amount of penetrating cryoprotectant was
gradually increased by 15% in each step [133]. The optimal vitrification solution consisted of
40% ethylene glycol and 0.6M sucrose. Three cooling rates (400°C/min and above) and three
warming rates (650°C/min and above), in combination with the proposed vitrification
solution, were equally effective. Optimization of the procedure and solution allowed
microencapsulated hepatocytes to be preserved with almost 100% retention of cell functions
and no detectable damage to the fragile microcapsules [55].
By applying this vitrification process, these authors were able to cryopreserve
hepatocytes in tissue engineering constructs, showing a good response to membrane integrity
and avoiding the usual apoptotic pathway triggered by cell detachment known as “anoikis”, a
447
key contributor to the rapid decrease in viability of primary mammalian hepatocytes after
isolation [67].
b) Subzero Non-freezing storage.
To date, few studies of hepatocyte preservation methods utilizing subzero nonfreezing
temperatures have been reported [40, 79, 104].This research is based on previous
investigations on nonfreezing storage of kidneys [12], heart [3, 106, 135] and liver [108, 116].
The general approach is the storage of isolated hepatocytes at temperatures between 0°C and
the freezing point of the sample (-Tsample °C). This method was originally reported by
Matsuda et al [80] using UW solution at -4°C. They preserved rat hepatocytes up to 48h in a
computer-programmed incubator which prevented ice formation in the -4°C range. They have
found improvements in the TB exclusion test, ATP contents, MTT assay and urea synthesis
during the rewarming of subzero nonfreezing group with respect to the UW (0°C) group. The
lactic acid production was suppressed in the subzero nonfreezing group with respect to the
0°C preserved group. The authors claimed that the subzero temperature protects hepatocytes
against hypoxic injury by suppression of cellular degradative catabolism in comparison with
conventional hypothermic preservation [80].
There are some limitations in the application of this method, because at subzero
temperatures without cryoprotective agents (CPA) the sample is in the supercooled state in
which the preservation solution is below the equilibrium freezing point but not yet frozen.
This metastable state poses the hazard of initiation of ice nucleation and freezing of the
sample at any time due to a slight impact or change in temperature. The addition of a CPA to
the preservation solution prevents ice formation and decreases the freezing point of the
solution. In this temperature range [∆ = 0°|C -T sample+ CPA °C] the solution is not susceptible to
ice nucleation, providing a safety zone for subzero nonfreezing temperature for cell/ organ
preservation. In this way, Rodriguez and Guibert [40, 104] have developed a methodology to
preserve rat hepatocytes at -4°C using 1,4-butanediol as CPA and UW solution. The first
approach was to develop a Gas Chromatography method to estimate the concentration of 1,4-
butanediol in the cells [2]. After that, it was determined: a- the effects of acute CPA exposure
at 37°C to explore the possibility of cryoprotector toxicity, and b- the penetration of the CPA
into the hepatocytes at -4°C. The CPA was added to the hepatic cells suspended in UW
solution at a low rate (0.16 g/min /110 .106 cells in 36 mL of UW) to get a final concentration
of 8% 1,4-butanediol. Then the hepatocytes were stored at -4°C up to 120 hours. The cellular
concentrations of glutathione, ATP content, glycogen and lactate production were determined
and compared with the results of conventional storage at 4°C. The results showed a significant
increase of ATP content, a considerable glycogen and glutathione retention and suppression
of lactic acid production in the cells stored at -4°C. These cells subjected to 60 min of
rewarming in Krebs-Henseleit resuspension media, maintained a viability similar to fresh
hepatocytes tested by propidium iodide test [38], glutathione and ATP content and functional
tests as MTT assay and ammonium removal efficiency (ARE). The activity and gene
expression of the urea cycle enzymes Carbamyl Phosphate synthetase I (CPSI) and Ornithine
Transcarbamylase (OTC) were also tested. Although the cells preserved at -4°C showed
initially, in the rewarming, diminished CPSI and OTC relative gene expression levels, they
were able, after 60 min, to return to values comparable to the controls. Also, after 60 min of
rewarming the ARE of preserved (-4°C) hepatocytes did not show differences with control
group.
In the end, these cells were appropriate for In vitro studies or bioartificial liver devices;
but not for hepatocellular transplantation, where an accumulation of macrophages were seen
around transplanted cells in recipients livers (personal observations).
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c) Storage in the Dry State
In Nature, some organisms have developed strategies to enable them to survive for long
periods at ambient temperatures in a desiccated state. This involves a complex phenotypic
response to environmental changes involving intracellular accumulation of cytoprotective
agents such as the disaccharide trehalose and amino acids [16]. However, transferring this
approach to mammalian cells raises several biological problems, which include how to
introduce such sugars into the intracellular compartment. Few studies have, so far, been made
in hepatocytes using such an approach, but Toner’s group [1] investigated a switchable cell
membrane pore to allow diffusion of high concentrations of trehalose into rat hepatocytes.
This allowed accumulation of trehalose up to 0.5M, but work on long-term dry storage has not
yet been reported.
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